2020 年第 5 期 第 15 卷

2型糖尿病患者血清微小RNA-31表达与肾病并发症及机体炎症水平的关系

Relation among serum microRNA-31 expression, diabetic nephropathy and inflammation in patients with type 2 diabetes mellitus

作者：马莹;白婧;常月

英文作者：Ma Ying Bai Jing Chang Yue

单位：河北省沧州市人民医院内分泌代谢科061000

英文单位：Department of Endocrinology and Metabolism Cangzhou People′s Hospital Hebei Province Cangzhou 061000 China

关键词：2型糖尿病；糖尿病肾病；微小RNA-31；炎症

英文关键词：Type2diabetesmellitus;Diabeticnephropathy;MicroRNA-31;Inflammation

• 摘要：

• 目的 探讨2型糖尿病患者血清微小RNA-31(miR-31)表达水平与并发糖尿病肾病（DN）的相关性，以及miR-31与机体炎症水平的相关性。方法 纳入2016年6月至2018年6月河北省沧州市人民医院的 2型糖尿病患者75例，其中无任何糖尿病相关血管并发症者25例（无并发症组），合并DN者25例（DN组），仅合并视网膜病变者25例（视网膜病变组）；另选取同期健康志愿者50例（对照组）。应用实时聚合酶链反应技术检测各组受试者血清miR-31表达水平，流式细胞仪检测血清肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）和细胞间黏附分子1（ICAM-1）水平。结果 对照组和2型糖尿病患者的血清miR-31表达量比较，差异无统计学意义(P＝0.528)。DN组的血清miR-31表达量明显低于无并发症组［（0.39±0.21）比（1.05±0.67）］（P=0.001），而视网膜病变组的血清miR-31表达量与无并发症组比较差异无统计学意义（P＝0.356）。DN组的血清ICAM-1水平明显高于无并发症组［（158.60±25.93）μg/L比（96.75±19.54）μg/L］（P＝0.001）。Pearson相关性分析结果 显示，DN组患者血清miR-31水平与TNF-α（r＝-0.614，P＝0.001）、IL-6（r＝-0.452，P＝0.026）、ICAM-1水平（r＝-0.540，P＝0.006）之间存在负相关。结论血清miR-31可作为2型糖尿病患者发生DN的生物学标志物，miR-31的表达与炎症因子TNF-α、IL-6、ICAM-1呈负相关。

• Objective To investigate the relation among serum microRNA-31(miR-31) expression, diabetic nephropathy（DN） and inflammation in patients with type 2 diabetes mellitus. Methods From June 2016 to June 2018, 75 patients with type 2 diabetes mellitus in Cangzhou People′s Hospital, Hebei Province were enrolled, including 25 cases without diabetic complication（non-complication group）, 25 cases with DN（DN group） and 25 cases with diabetic retinopathy（DR group）; 50 healthy people were enrolled as control group. Serum miR-31 expression was detected by real-time polymerase chain reaction. Levels of serum tumor necrosis factor-α（TNF-α）, interleukin-6（IL-6） and intercellular adhesion molecule-1（ICAM-1） were detected by flow cytometry. Results There was no significant difference in serum miR-31 expression between the control group and diabetic patients(P＝0.528). Serum miR-31 expression in the DN group was significantly lower than that in the non-complication group［（0.39±0.21） vs （1.05±0.67）］（P=0.001）. There was no significant difference in serum miR-31 expression between the DR group and control group（P＝0.356）. Serum ICAM-1 level in the DN group was significantly higher than that in the non-complication group［（158.60±25.93）μg/L vs （96.75±19.54）μg/L］（P＝0.001）. Pearson analysis showed that serum miR-31 expression in the DN group was negatively correlated with TNF-α（r＝-0.614, P＝0.001）, IL-6（r＝-0.452, P＝0.026） and ICAM-1（r＝-0.540, P＝0.006）. Conclusions Serum miR-31 can be used as a biomarker of DN in patients with type 2 diabetes mellitus. Expression of miR-31 is negatively correlated with inflammatory molecules TNF-α, IL-6 and ICAM-1.